Clinical trial
A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain
NCT02620020 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- January 26, 2016
- Completion date
- September 13, 2017
- Enrollment
- 563 (actual)
- Sites
- 74
Conditions
As the registry lists them; a condition with its own page is linked.